Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.33 |
| ▸ | CYBB | P04839 | 1/20 | 0.33 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 0.33 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.33 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 3/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532671 | 0.85 | IDO1 (0.40) | PTPN1GSK3BIDO1PTPN5TAAR1 | |
| SCHEMBL27705804 | 0.79 | PTPN1 (0.39) | PTPN1GSK3BIDO1PTPN5SIRT2 | |
| SCHEMBL27546311 | 0.79 | IDO1 (0.54) | PTPN1GSK3BIDO1PTPN5SIRT2 | |
| SCHEMBL25090301 | 0.78 | SLC6A4 (0.41) | PTPN1GSK3BIDO1PTPN5DAO | |
| SCHEMBL12650016 | 0.77 | ESR1 (0.40) | IDO1PTPN5CYP3A4CYP2D6DAO | |
| SCHEMBL531384 | 0.77 | KLF10 (0.40) | IDO1PTPN5SIRT2CYP3A4CYP2D6 | |
| SCHEMBL28035154 | 0.77 | IDO1 (0.40) | IDO1PTPN5CYBBNOX3NOX4 | |
| SCHEMBL27975927 | 0.76 | DAO (0.51) | PTPN1GSK3BIDO1PTPN5SIRT2 | |
| SCHEMBL5440588 | 0.76 | IDO1 (0.54) | PTPN1GSK3BIDO1PTPN5SIRT2 | |
| SCHEMBL5426897 | 0.74 | DAO (0.52) | PTPN1GSK3BIDO1PTPN5SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| CN-104557757-A | CETP inhibitors | MERCK & CO INC | 2015-04-29 | — | — | CN | disclosed |
| CN-104447603-A | CETP inhibitors | MERCK SHARP & DOHME | 2015-03-25 | — | — | CN | disclosed |
| CN-102304096-B | CETP inhibitors | MERCK SHARP & DOHME | 2014-12-03 | — | — | CN | disclosed |
| CN-102311401-B | CETP inhibitors | MERCK & CO INC | 2014-12-03 | — | — | CN | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| CN-102311401-A | CETP INHIBITORS | MERCK & CO INC | 2012-01-11 | — | — | CN | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| CN-101365689-A | 1,3-oxazolidin-2-one derivatives useful as cetp inhibitors | MERCK & CO INC (US) | 2009-02-11 | — | — | CN | disclosed |
| CN-101228131-A | Novel heterocyclylideneacetamide derivatives | MOCHIDA PHARM CO LTD (JP) | 2008-07-23 | — | — | CN | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| CN-1980904-A | CETP inhibitors | MERCK & CO INC (US) | 2007-06-13 | — | — | CN | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014357-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | PTPN1 3029/4885GSK3B 3127/4885IDO1 4683/4885 |
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | PTPN1 3029/4885GSK3B 3127/4885IDO1 4683/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | PTPN1 3029/4885GSK3B 3127/4885IDO1 4683/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | PTPN1 3029/4885GSK3B 3127/4885IDO1 4683/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | PTPN1 3029/4885GSK3B 3127/4885IDO1 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.